Phase I–II study of docetaxel and ifosfamide combination in patients with anthracycline pretreated advanced breast cancer

Given the established individual activity of docetaxel and ifosfamide in anthracycline pretreated advanced breast cancer, the present phase I–II study aimed to define the maximum tolerated dose (MTD), the dose-limiting toxicities (DLTs), and activity of the docetaxel–ifosfamide combination in this s...

Celý popis

Uloženo v:
Podrobná bibliografie
Hlavní autoři: Kosmas, C, Tsavaris, N, Malamos, N, Stavroyianni, N, Gregoriou, A, Rokana, S, Polyzos, A
Médium: Artigo
Jazyk:Inglês
Vydáno: Nature Publishing Group 2003
Témata:
Clinical
On-line přístup:https://ncbi.nlm.nih.gov/pmc/articles/PMC2747562/
https://ncbi.nlm.nih.gov/pubmed/12698179
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1038/sj.bjc.6600887
Tagy: Přidat tag
Žádné tagy, Buďte první, kdo otaguje tento záznam!

Podobné jednotky